Strides Pharma

Why is Strides Pharma Science Ltd falling/rising?

As of 06-Jul, Strides Pharma Science Ltd's stock price is at 1,121.50, down 0.48%, following a trend reversal after three days of gains and a significant drop in investor participation. Despite strong long-term financial performance, including a 54.96% net profit growth over the last 11 quarters, recent profit declines may be impacting the stock's current downward movement.

As of 06-Jul, Strides Pharma Science Ltd's stock price is currently at 1,121.50, reflecting a decrease of 5.4 points or 0.48%. The stock has underperformed its sector today by 0.89% and has experienced a trend reversal, falling after three consecutive days of gains. This decline is further supported by a significant drop in investor participation, with the delivery volume on July 3 falling by 49.52% compared to the five-day average.<BR><BR>Despite these short-term challenges, the company has shown strong financial performance over the longer term. It reported a net profit growth of 54.96% and has declared positive results for the last 11 consecutive quarters. The stock has generated a return of 26.55% over the past year, outperforming the BSE500 in each of the last three annual periods. However, it is important to note that while the stock has performed well historically, its profits have decreased by 14.9% over the same period, which may contribute to the current price decline.<BR><BR>Overall, the combination of recent underperformance, reduced investor participation, and profit declines may be influencing the stock's current downward movement, despite its strong historical returns and positive financial indicators.

Which are the latest news on Strides Pharma?

How big is Strides Pharma?

As of 10th June, Strides Pharma Science Ltd has a market capitalization of 9,340.00 Cr, with recent net sales of 4,858.69 Cr and net profit of 556.19 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Strides Pharma Science Ltd has a market capitalization of 9,340.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 4,858.69 Cr, while the sum of Net Profit for the same period is 556.19 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds are valued at 2,551.83 Cr, and Total Assets amount to 5,779.59 Cr.

Who are in the management team of Strides Pharma?

The management team of Strides Pharma includes Arun Kumar (Chairperson & Managing Director), S Sridhar, Bharat D Shah, Homi Rustam Khusrokhan (all Non-Executive & Independent Directors), Manjula Ramamurthy (Company Secretary), Badree Komandur (Executive Director, Finance), and Kausalya Santhanam (Non-Executive & Independent Director). They are responsible for guiding the company's strategy and ensuring regulatory compliance.

The management team of Strides Pharma includes the following key individuals:<BR><BR>1. **Arun Kumar** - Chairperson & Managing Director<BR>2. **S Sridhar** - Non-Executive & Independent Director<BR>3. **Bharat D Shah** - Non-Executive & Independent Director<BR>4. **Manjula Ramamurthy** - Company Secretary & Compliance Officer<BR>5. **Homi Rustam Khusrokhan** - Non-Executive & Independent Director<BR>6. **Badree Komandur** - Executive Director (Finance)<BR>7. **Kausalya Santhanam** - Non-Executive & Independent Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and ensuring compliance with regulatory standards.

Who are the peers of the Strides Pharma?

Strides Pharma's peers include Viyash Scientifi, Shilpa Medicare, Sanofi Consumer, P & G Health Ltd, Akums Drugs, Blue Jet Health, Supriya Lifesci, and Sanofi India. Most peers show Below Average growth and management risk, with Viyash Scientifi having the highest 1-year return at 26.25%, while Strides Pharma's return is 14.94%.

Peers: The peers of Strides Pharma are Viyash Scientifi, Shilpa Medicare, Sanofi Consumer, P & G Health Ltd, Akums Drugs, Blue Jet Health, Supriya Lifesci., and Sanofi India.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sanofi Consumer, P & G Health Ltd, and Sanofi India, while Good management risk is found at Blue Jet Health and Supriya Lifesci. Average management risk is present at Viyash Scientifi and Akums Drugs, and Below Average management risk is noted at Shilpa Medicare. All peers exhibit Below Average growth except for Supriya Lifesci and Blue Jet Health, which have Good growth, while the rest have Below Average growth. Capital Structure ratings show Excellent at Sanofi Consumer, P & G Health Ltd, Blue Jet Health, and Supriya Lifesci, Good at Akums Drugs, and Below Average at Viyash Scientifi, Shilpa Medicare, and Strides Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Viyash Scientifi at 26.25%, while the lowest is Sanofi India at -48.66%. Strides Pharma's 1-year return of 14.94% is higher than that of Sanofi India but lower than Viyash Scientifi. Additionally, Blue Jet Health and Sanofi India have negative six-month returns.

What does Strides Pharma do?

Strides Pharma Science Ltd is a small-cap pharmaceutical company that specializes in the development and manufacturing of generic and specialty drugs. As of March 2026, it reported net sales of ₹1,323 Cr and a net profit of ₹127 Cr, with a market cap of ₹9,340 Cr.

Overview: <BR>Strides Pharma Science Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History: <BR>Strides Pharma Science Limited was originally incorporated as 'Strides Arcolab Limited' in 1990. The company underwent a merger with Shasun Pharmaceuticals Limited in FY 2016, resulting in the formation of 'Strides Shasun Limited' on November 19, 2015. The name was changed to 'Strides Pharma Science Limited' on July 18, 2018. The most recent quarterly results reported net sales and profit for March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 1,323 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 127 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 9,340 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 16.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.39% <BR>Debt-Equity: 0.50 <BR>Return on Equity: 18.64% <BR>Price to Book: 3.04<BR><BR>Contact Details: <BR>Address: No 201 Devavrata Sector 17, Vashi Navi Mumbai Maharashtra : 400703 <BR>Tel: 91-22-27892924/27893199 <BR>Email: investors@stridesshasun.com <BR>Website: http://www.stridesarco.com

Are Strides Pharma Science Ltd latest results good or bad?

Strides Pharma Science Ltd's latest results show strong revenue growth with net sales of ₹1,323.47 crores in Q4 FY26, but net profit declined sequentially by 37.19% due to a significant drop in other income, raising concerns about profitability sustainability and margin pressures. While the revenue increase is positive, investors should be cautious of the operational challenges ahead.

Strides Pharma Science Ltd's latest results present a mixed picture. On one hand, the company achieved a significant milestone with net sales reaching ₹1,323.47 crores in Q4 FY26, marking an impressive 11.18% year-on-year growth and 10.78% sequential growth, which is the highest quarterly revenue in its recent history. This indicates strong demand and effective market penetration.<BR><BR>However, the net profit for the same quarter was ₹126.94 crores, which, while showing a healthy year-on-year increase of 54.45%, reflects a sharp sequential decline of 37.19%. This decline was primarily due to a drastic drop in other income, which fell from ₹106.86 crores in the previous quarter to just ₹8.13 crores. This volatility in earnings raises concerns about the sustainability of profitability.<BR><BR>Additionally, the operating margin, excluding other income, decreased to 18.11% from 19.75% in the previous quarter, indicating challenges in managing costs and pricing pressures in key markets. <BR><BR>Overall, while the revenue growth is commendable and suggests robust demand, the volatility in profit and margin compression highlight underlying operational challenges that the company needs to address. Investors may view this as a promising turnaround story, but the execution risks and margin stability will be critical to monitor in the coming quarters.

Should I buy, sell or hold Strides Pharma Science Ltd?

When is the next results date for Strides Pharma Science Ltd?

The next results date for Strides Pharma Science Ltd is 18 May 2026.

The next results date for Strides Pharma Science Ltd is scheduled for 18 May 2026.

Is Strides Pharma technically bullish or bearish?

As of November 27, 2025, Strides Pharma's technical trend is mildly bullish, supported by bullish weekly and monthly MACD and moving averages, despite some mixed signals from other indicators.

As of 27 November 2025, the technical trend for Strides Pharma has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is also bullish, indicating positive momentum. The daily moving averages are bullish, supporting the mildly bullish stance. However, the KST and OBV on a weekly basis are mildly bearish, which introduces some caution. Dow Theory shows a mildly bearish signal on the weekly chart but is bullish on the monthly chart. Overall, the current technical stance is mildly bullish, driven primarily by the bullish MACD and moving averages, despite some mixed signals from other indicators.

Is Strides Pharma overvalued or undervalued?

As of November 3, 2025, Strides Pharma is considered very attractive and undervalued, with a PE ratio of 20.76 and a PEG ratio of 0.00, significantly outperforming competitors like Sun Pharma and Cipla, and achieving a year-to-date return of 49.33% compared to the Sensex's 7.47%.

As of 3 November 2025, the valuation grade for Strides Pharma has moved from attractive to very attractive, indicating a positive shift in its market perception. The company is currently considered undervalued, particularly when examining its key financial ratios. Strides Pharma has a PE ratio of 20.76, a price to book value of 0.33, and an EV to EBITDA of 23.05, which suggest that it is trading at a significant discount compared to its peers.<BR><BR>In comparison to notable competitors, Sun Pharma has a PE ratio of 35.62 and an EV to EBITDA of 24.18, while Cipla shows a PE of 22.44 and an EV to EBITDA of 5.66. This highlights that Strides Pharma is positioned favorably within the industry, especially with its PEG ratio at 0.00, suggesting strong growth potential relative to its price. Additionally, Strides Pharma has outperformed the Sensex in various timeframes, including a year-to-date return of 49.33% compared to the Sensex's 7.47%, reinforcing the notion of its undervaluation.

How has been the historical performance of Strides Pharma?

Strides Pharma has shown significant recovery and growth, with net sales increasing from 2,178.37 crore in March 2019 to 4,565.34 crore in March 2025, and profit after tax rebounding to 407.57 crore in March 2025 from a loss of 89.94 crore the previous year. The company's operating profit also improved to 802.82 crore in March 2025, indicating strong financial performance.

Answer:<BR>The historical performance of Strides Pharma shows a significant recovery and growth trajectory in recent years, particularly in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Strides Pharma's net sales have shown a consistent upward trend, increasing from 2,178.37 crore in March 2019 to 4,565.34 crore in March 2025. Total operating income followed a similar pattern, reaching 4,565.34 crore in March 2025, up from 3,890.13 crore in March 2024. The company's total expenditure also rose, amounting to 3,762.52 crore in March 2025, which is higher than the previous year's 3,307.75 crore. Operating profit (PBDIT) excluding other income improved significantly to 802.82 crore in March 2025, compared to 582.38 crore in March 2024, indicating a recovery from a loss of 20.11 crore in March 2022. Profit before tax turned positive at 485.08 crore in March 2025, a notable improvement from a loss of 60.83 crore in March 2024. The profit after tax also rebounded to 407.57 crore in March 2025, compared to a loss of 89.94 crore in the previous year. The company's total assets increased to 5,779.59 crore in March 2025 from 5,572.41 crore in March 2024, while total liabilities slightly increased to 5,779.59 crore from 5,572.41 crore. Cash flow from operating activities remained positive at 684.00 crore in March 2025, although net cash outflow was recorded at -48.00 crore. Overall, Strides Pharma's financial performance reflects a strong recovery and growth in key areas, particularly in sales and profitability.

Who are the top shareholders of the Strides Pharma?

The top shareholders of Strides Pharma include Pronomz Ventures LLP with 19.58%, foreign institutional investors holding 28.32%, and mutual funds at 8.89%. Individual investors own 21.51% of the shares, with Quant Mutual Fund being the largest public shareholder at 5.4%.

The top shareholders of Strides Pharma include a mix of institutional and individual investors. The largest promoter holding is Pronomz Ventures LLP, which holds 19.58%. The company has a significant portion of its shares pledged by promoters, amounting to 51.9788%. <BR><BR>In terms of institutional investors, mutual funds hold about 8.89% of the shares through 11 different schemes, while foreign institutional investors (FIIs) account for 28.32% of the holdings, represented by 228 FIIs. The highest public shareholder is Quant Mutual Fund, specifically the Quant Business Cycle Fund, which holds 5.4%. Additionally, individual investors collectively hold 21.51% of the shares.

Has Strides Pharma declared dividend?

Strides Pharma Science Ltd has declared a 25% dividend, amounting to ₹2.5 per share, with an ex-date of September 9, 2024. Despite low dividend yields, the company has shown strong price appreciation, with total returns of 86.82% over the past year and 355.21% over the last two years.

Strides Pharma Science Ltd has declared a 25% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 25%<BR>- Amount per share: 2.5<BR>- Ex-date: Sep-09-2024<BR><BR>Dividend Yield: 0.32%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 10.3%, with a dividend return of 0%, resulting in a total return of 10.3%.<BR><BR>Over the past year, the price return was 86.26%, the dividend return was 0.56%, leading to a total return of 86.82%.<BR><BR>In the 2-year period, the price return stood at 353.24%, with a dividend return of 1.97%, culminating in a total return of 355.21%.<BR><BR>For the 3-year period, the price return was 402.18%, the dividend return was 2.81%, resulting in a total return of 404.99%.<BR><BR>In the last 4 years, the price return was 108.0%, with a dividend return of 1.75%, giving a total return of 109.75%.<BR><BR>Over the past 5 years, the price return reached 292.97%, while the dividend return was 4.29%, leading to a total return of 297.26%.<BR><BR>Overall, Strides Pharma has declared a dividend, and the total returns over various periods indicate strong price appreciation, particularly in the longer term, despite relatively low dividend returns.